Transparent Meds review

Transparent Meds provides enough public information to compare its compounded weight-care model, including named partners and detailed cancellation rules. The strongest reason to pause before purchase is the gap between its broad refund promise and written fee exclusions, alongside an unresolved clinical-entity inconsistency. Get those answers in writing before treating the low monthly offer as a commitment.

Transparent Meds LLC describes itself in its terms as a technology platform connecting patients with independent clinicians and pharmacies. The site footer names Locum Tele as its clinical network and Rush Pharmacy as its dispensing partner. Those are company disclosures, rather than independent license verification or confirmation of an individual assignment. There is also a meaningful inconsistency: the May 2026 telehealth consent labels Transparent Meds LLC itself as the provider entity, while the terms and footer say the company is not a healthcare provider. Ask which medical practice establishes the patient relationship, who holds the records and which clinician is responsible for prescribing. An identifiable brand and a named partner do not resolve that discrepancy. The broader website sells several other treatment categories; their presence does not establish that an additional product belongs in an individual weight-care plan.

The advertised sequence is an online assessment, licensed-provider review and delivery if prescribed, with ongoing follow-ups. Terms allow real-time video, audio or asynchronous consultations, so do not assume every review involves a video appointment. The expanded FAQ says laboratory tests or in-person steps are ordered when the clinician considers them appropriate. Ask what information is required before the first prescription and whether testing has a separate cost. Follow-up access is useful only if the patient knows how to reach the clinical team and when to expect an answer. Request that process, the refill review schedule and a plan for concerns between shipments. The service is intended for adults eighteen or older. The expanded state FAQ lists forty-five states, omitting Alaska, Louisiana, Mississippi, New Hampshire and New Mexico. Confirm availability for the particular treatment and your physical location. A stated BMI requirement appears in the terms without a numerical threshold, so completing an assessment cannot be treated as assured eligibility.

The homepage displays $99 monthly for semaglutide and $199 for tirzepatide alongside crossed-out higher amounts. It says medication is included when prescribed, while final cost and treatment depend on clinician review. A dose-specific continuing-price schedule and promotional duration were not established on the public pages. Ask for the first charge, the next renewal and the amount if the prescribed dose changes. The homepage promotes free shipping and unlimited follow-ups, but the terms authorize additional fees such as expedited delivery or additional consultations. Request an explanation of which contacts are included and which could generate another charge. The terms say the company does not submit insurance claims; receipts may support a patient’s own reimbursement request, without guaranteeing coverage. Subscription payments are taken in advance. Cancel future renewals in the account or contact support at least forty-eight hours before the next billing date, as described in the refund policy. The homepage says patients unsuitable for treatment are eligible for a full refund. The formal refund policy instead says medication and pharmacy charges may be refunded after denial, while platform or provider fees may remain nonrefundable or only partly refundable. This is a material conflict. Ask for the actual retained amount before authorizing payment. Clinical review can restrict cancellation even before shipment, and pharmacy processing can close the medication-refund window. There are no prorated refunds for an unused current cycle. For incorrect or damaged deliveries, the policy asks patients to contact support within forty-eight hours and may require evidence; preserve the packaging and order details.

The primary program is explicitly compounded semaglutide and tirzepatide, and the website acknowledges that compounded preparations are not FDA-approved. References to FDA-registered facilities, clinician guidance or research on branded medicines do not establish FDA approval of the supplied preparation. FDA says compounded GLP-1 medicines should be used only when an approved drug cannot meet a patient’s medical needs. Ask the prescriber to explain the patient-specific rationale and identify the actual formulation, concentration and dispensing pharmacy. The public molecule names alone do not establish additives or the exact product supplied. Obtain instructions that match the prescription and label, including how the dose is measured, storage and whom to contact about a questionable shipment. FDA has reported dosing errors involving compounded injectable semaglutide; a lower price is not a substitute for clear administration instructions. Neither the website’s projection tool nor testimonials establish an individual outcome or comparative effectiveness of this program.